Value through Innovation04 February 2016

Uncovering Answers to Protect Patients' Health

Boehringer Ingelheim has a large and experienced global team managing and conducting clinical trials in many indications. During the past decade from 2005 to 2014, Boehringer Ingelheim conducted or sponsored 1,414 studies with approximately one million patients on 115 substances in 95 countries.

Clinical Trials in detail

  • Basic Information

    Boehringer Ingelheim conducts and sponsors clinical trials to establish safety and efficacy of the drugs we develop, either for use in their initial indication or in additional indications.

  • Clinical Trial Results

    In compliance with our Policy on Transparency and Publication of Clinical Study Data, Boehringer Ingelheim is committed to disclosing all study results independent of outcome. Responsible sharing of de-identified clinical study data and redacted clinical documents are reported.

  • Frequent asked Questions - FAQ

    Find Answers to frequently asked questions about Clinical Trials.

  • Glossary

    Find out more about key terms in connection with Clinical Trials in our Glossary.

  • Transparency Policy

    To benefit patients, public health, and to foster scientific discovery, Boehringer Ingelheim is committed to responsible sharing of clinical study reports (CSRs), related clinical documents, and patient-level clinical study data after drug approval or after termination of the drug development program.

Oncology Websites

No flash player detected. For optimized usage of this website your browser should support shockwave flash. For downloading see Macromedia Flash Player